13F Pro13F Pro

Defilade Capital Management, L.P.

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2088557
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare94.4%$704.9M
  • Technology5.6%$42.0M

AUM History

13fpro.ai/research/fund/defilade-capital-management-l-p-2088557

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/defilade-capital-management-l-p-2088557

Defilade Capital Management, L.P. 13F holdings — Q2 2026

$746.9M portfolio (+4.9% QoQ) · 39 holdings · Q2 2026 13F · top 10 are 47% of the stock portfolio

All holdings — Defilade Capital Management, L.P. (Q2 2026)

39 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ABT$ABTABBOTT LABORATORIES$25.9MNew
ASND$ASNDAscendis Pharma A/S$25.3M+83%
SOLV$SOLVSolventum Corp$24.4MNew
MDT$MDTMedtronic plc$23.7MNew
ELAN$ELANElanco Animal Health Inc$21.3M-7%
AGIO$AGIOAGIOS PHARMACEUTICALS, INC.$20.3MNew
NVST$NVSTEnvista Holdings Corp$19.1MNew
RVMD$RVMDRevolution Medicines, Inc.$15.5M-74%
ICUI$ICUIICU MEDICAL INC/DE$15.5M-58%
COGT$COGTCogent Biosciences, Inc.$15.2M+12%
LNTH$LNTHLantheus Holdings, Inc.$14.7M-47%
OCUL$OCULOCULAR THERAPEUTIX, INC$14.6M+0.2%
ELDN$ELDNEledon Pharmaceuticals, Inc.$13.9M-1%
TYRA$TYRATyra Biosciences, Inc.$12.0MNew
OLMA$OLMAOlema Pharmaceuticals, Inc.$11.6M-39%

What changed in Q2 2026

Against the previous quarter's 13F: 19 new, 9 added to, 10 trimmed, 11 sold out. Share-count changes; largest moves by dollar size first.

New positions (19)

  • VEEV$VEEVVEEVA SYSTEMS INC$42.0M

    first bought this quarter

  • BMRN$BMRNBIOMARIN PHARMACEUTICAL INC$39.0M

    first bought this quarter

  • BAX$BAXBAXTER INTERNATIONAL INC$31.1M

    first bought this quarter

  • PODD$PODDINSULET CORP$26.9M

    first bought this quarter

  • TMO$TMOTHERMO FISHER SCIENTIFIC INC.$26.0M

    first bought this quarter

  • ABT$ABTABBOTT LABORATORIES$25.9M

    first bought this quarter

+13 more in the Excel export

Added to (9)

  • LLY$LLYELI LILLY & Co+89%

    now $46.9M · held 3+ qtrs

  • ASND$ASNDAscendis Pharma A/S+83%

    now $25.3M · held 3+ qtrs

  • INSM$INSMINSMED Inc+45%

    now $30.0M · held 3+ qtrs, 2 adds in a row

  • PFE$PFEPFIZER INC+21%

    now $42.7M · held 3+ qtrs

  • PTCT$PTCTPTC THERAPEUTICS, INC.+15%

    now $35.4M · held 2 qtrs, 2 adds in a row

  • ORIC$ORICOric Pharmaceuticals, Inc.+24%

    now $11.3M · held 2 qtrs, 2 adds in a row

+3 more in the Excel export

Trimmed (10)

  • RVMD$RVMDRevolution Medicines, Inc.-74%

    now $15.5M · held 3+ qtrs, 2 trims in a row

  • DNLI$DNLIDenali Therapeutics Inc.-71%

    now $10.1M · held 3+ qtrs

  • ZBH$ZBHZIMMER BIOMET HOLDINGS, INC.-45%

    now $27.3M · held 2 qtrs

  • ICUI$ICUIICU MEDICAL INC/DE-58%

    now $15.5M · held 3+ qtrs, 2 trims in a row

  • GMED$GMEDGLOBUS MEDICAL INC-61%

    now $11.0M · held 3+ qtrs

  • PACS$PACSPACS Group, Inc.-64%

    now $9.2M · held 3+ qtrs, 2 trims in a row

+4 more in the Excel export

Sold out (11)

  • HSIC$HSICHENRY SCHEIN INCwas $46.0M

    held 2+ qtrs

  • BDX$BDXBECTON DICKINSON & COwas $43.9M

    held 2+ qtrs

  • DXCM$DXCMDEXCOM INCwas $33.8M

    held 2+ qtrs

  • ISRG$ISRGINTUITIVE SURGICAL INCwas $31.2M

    held 2+ qtrs

  • NBIX$NBIXNEUROCRINE BIOSCIENCES INCwas $27.7M

    held 1 qtr

  • ITGR$ITGRInteger Holdings Corpwas $18.7M

+5 more in the Excel export

Firm AUM (Form ADV): $1.5B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Defilade Capital Management, L.P. has filed, 2 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Defilade Capital Management, L.P.?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Defilade Capital Management, L.P.'s top 20 holdings: 59/100 (our AI quality score, weighted by position size; 18 of the 20 are scored)

Top 10 since filing

+1.4%

Value-weighted move of the 10 largest stock positions

Turnover

58%

Last quarter

Top 10 weight

47%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Defilade Capital Management, L.P. disclosed 39 positions worth $746.9M in its Form 13F-HR for Q2 2026, led by $LLY (ELI LILLY & Co) at 6.3% of the equity portfolio, followed by $PFE and $VEEV. During the quarter the fund opened 19 new positions and exited 11 — including a new stake in $VEEV and a full exit from $HSIC. The portfolio is most concentrated in Healthcare (94.4% of disclosed assets). All figures are sourced directly from Defilade Capital Management, L.P.’s Form 13F-HR filing with the SEC under CIK 2088557.

Funds like this

managers whose biggest positions overlap Defilade Capital Management, L.P.'s
Vestal Point Capital, LP$4.28B 13F book · 7 shared top holdingsBMRNABTZBHPODDSECTOR GAMMA AS$460.97M 13F book · 8 shared top holdingsPFEBMRNTMOMDTFARALLON CAPITAL MANAGEMENT LLC$21.68B 13F book · 5 shared top holdingsTMORVMDLNTHAGIORTW INVESTMENTS, LP$11.71B 13F book · 3 shared top holdingsPTCTINSMCOGTBellevue Group AG$4.75B 13F book · 6 shared top holdingsINSMRVMDABTMDTDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 7 shared top holdingsRVMDCOGTLRMRLNTH

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Defilade Capital Management, L.P.

13F Pro is an AI hedge fund tracker and stock research platform. For Defilade Capital Management, L.P. (SEC CIK: 2088557), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Defilade Capital Management, L.P.'s portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.